Thalictoside
Thalictoside is found in A. squamosa L. Thalictoside is a sEH inhibitor (IC50: 20.2 µM). Thalictoside exerts anti-osteoporotic effects through an estrogen-like mechanism. Thalictoside can be used in the research of cardiovascular and urinary diseases.
For research use only. We do not sell to patients.
- CAS No.: 74213-96-0
- Formula: C14H19NO8
- Molecular Weight:329.30
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Chemical Information
-
CAS No. 74213-96-0
-
Molecular Weight 329.30
-
Formula C14H19NO8
-
SMILES
O[C@H]1[C@H](O)[C@@H](O)[C@H](OC2=CC=C(CC[N+]([O-])=O)C=C2)O[C@@H]1CO
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)